Insulet | PODD - Gewinn Vor Steuern

Aktienkurs
154.32
Täglich Wechseln
-2.27 -1.45%
Monatlich
-19.76%
Jährlich
-52.44%
Q2 Prognose
144.50




Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.39B 27M 2026-03
Align Technology USD 148.89M 27.71M 2026-03
AtriCure USD 394K 1.97M 2026-03
Avanos Medical USD 1.2M 2.4M 2025-12
Baxter International USD -756M 877M 2025-12
Becton, Dickinson and Co. USD 393M 117M 2025-12
Boston Scientific USD 700M 238M 2025-12
Cardinal Health USD 630M 32M 2025-12
Cooper Companies USD 116.8M 137.4M 2025-09
Dexcom USD 340.7M 40.7M 2025-12
Edwards Lifesciences USD 348.4M 51.8M 2025-09
Eli Lilly USD 8.27B 1.03B 2025-12
Globus Medical USD 169.23M 25.24M 2025-12
ICU Medical USD -15.9M 86.2M 2025-12
Inogen USD -6.06M 467K 2024-09
Insulet USD 113M 27.2M 2026-03
Integra LifeSciences USD -2.41M 6.72M 2026-03
J&J USD 7.82B 2.86B 2026-03
Masimo USD 71.3M 3.6M 2026-03
Medtronic USD 2.1B 224M 2025-09
Merit Medical Systems USD 51.06M 22.12M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Solventum Corp USD 332M 179M 2025-12
Stryker USD 1.7B 676M 2025-12
Tandem Diabetes Care USD 4.68M 29.82M 2025-12
Teleflex USD 218.94M 657.52M 2025-12
West Pharmaceutical Services USD 161.5M 8.6M 2025-12
Zimmer Biomet Holdings USD 98M 320.7M 2025-12